Industry Roundup: GMP Warning, MedGen/Alternaturals Merger
This article was originally published in The Tan Sheet
Executive Summary
FDA finds chaos at Chaotic Labz; investor facilitates MedGen, Alternaturals combination; more news in brief.
You may also be interested in...
FDA Holds Marketers Responsible For Manufacturers’ GMP Violations
FDA has begun holding own-label dietary supplement marketers responsible for their contract manufacturers’ violations of good manufacturing practices.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.